✦ LIBER ✦

Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?

✍ Scribed by Volker Diehl; Michael Fuchs

Book ID: 116928640
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 109 KB
Volume: 37
Category: Article
ISSN: 1473-0502
DOI: 10.1016/j.transci.2007.04.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early chemotherapy intensification with

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

✍ Andrea Gallamini; Caterina Patti; Simonetta Viviani; Andrea Rossi; Francesca Fio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

SURVEILLANCE CAN BE THE STANDARD OF CARE

SURVEILLANCE CAN BE THE STANDARD OF CARE FOR STAGE I NONSEMINOMATOUS TESTICULAR TUMORS AND EVEN HIGH RISK PATIENTS

✍ ROELEVELD, TON A.; HORENBLAS, SIMON; MEINHARDT, WIM; van de VIJVER, MARK; KOOI, 📂 Article 📅 2001 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 63 KB

Can RCSEng standards for the management

Can RCSEng standards for the management of high risk general surgical patients be achieved in UK hospitals?

✍ Abdelrahman, Tarig; Griffiths, Angharad; Davies, Lowri; Furtado, Sanjay; Henwood 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Two different schedules for integrating

Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy

✍ Guy Cantin; Bernard L'Espérance; Louise Yelle; Louis Desjardins; Félix Couture; 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 134 KB

Advanced Stage Is the Most Important Pro

Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin’s Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy

✍ José-Tomás Navarro; Josep-Maria Ribera; Albert Oriol; Blanca Xicoy; José-Luis Ma 📂 Article 📅 2007 🏛 Carden Jennings Publishing 🌐 English ⚖ 237 KB

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin’s lymphoma: Abstracted from: Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. Journal of Clinical Oncology 2003; 21: 2320–2325

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 83 KB